Imatinib Dosing Recommendations for Chronic‑Phase Chronic Myeloid Leukemia

Efficacy of High‑Dose Imatinib

• In the TOPS randomized trial of 476 adults with newly diagnosed chronic‑phase CML, initiating therapy with 800 mg imatinib daily produced a faster major molecular response (MMR) at 3 and 6 months compared with the standard 400 mg dose, but this advantage disappeared by 12 months (MMR 46 % vs 40 %; complete cytogenetic response 70 % vs 66 %; differences not statistically significant)【1】.
  Evidence level: Phase III randomized controlled trial (high‑quality).

Safety and Tolerability of High‑Dose Imatinib

• The same TOPS trial showed that only 62 % of patients remained on the assigned 800 mg dose at 12 months, versus 85 % on the 400 mg dose, primarily because of increased toxicity with the higher dose【1】.
  Evidence level: Phase III randomized controlled trial (high‑quality).

Guideline Recommendation

• The National Comprehensive Cancer Network (NCCN) designates imatinib 400 mg once daily as a Category 1 recommendation for the initial treatment of chronic‑phase CML, reflecting high‑level evidence and uniform consensus. The NCCN panel also concluded that interferon should no longer be used as initial therapy given imatinib’s excellent long‑term outcomes【1】.
  Evidence level: Guideline Category 1 (strongest recommendation).